Treatment and pharmacologic management of BPH in the context of common comorbidities

American Journal of Managed Care

Volumn 12, Issue SUPPL. 5, 2006, Pages

  O'Leary, Michael P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PLACEBO; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TERAZOSIN;

AGING; ALLERGIC REACTION; ARTICLE; ASTHENIA; COMORBIDITY; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG WITHDRAWAL; DYSPNEA; EJACULATION DISORDER; ERECTILE DYSFUNCTION; FATIGUE; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; HYPOTENSION; MALAISE; MINIMALLY INVASIVE SURGERY; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; POSITIONAL DIZZINESS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RETROGRADE EJACULATION; SOMNOLENCE; SYSTEMATIC REVIEW; THORAX PAIN; TRANSURETHRAL MICROWAVE THERMOTHERAPY; TRANSURETHRAL NEEDLE ABLATION; TRANSURETHRAL RESECTION; URETHRA STRICTURE; URINE INCONTINENCE; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; AZASTEROIDS; CARDIOVASCULAR DISEASES; COMORBIDITY; DOXAZOSIN; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FINASTERIDE; HUMANS; IMPOTENCE; MALE; PRAZOSIN; PROSTATIC HYPERPLASIA; QUINAZOLINES; SULFONAMIDES; TESTOSTERONE 5-ALPHA-REDUCTASE; TRANSURETHRAL RESECTION OF PROSTATE; TREATMENT OUTCOME; WORLD HEALTH;

EID: 33645956541     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. O'Leary MP. LUTS, ED, QOL: alphabet soup or real concerns to aging men? Urology. 2000;56(5 suppl 1):7-11.
2. Wei JT, Calhoun E, Jacobsen SJ. Urologic Diseases in America project: benign prostatic hyperplasia. J Urol. 2005;173:1256-1261.
3. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol. 2003;170(2 Pt 1):530-547.
4. 1-adrenoreceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol. 1996;29:129-144.
5. Boyle P, Napalkov P. The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension. Scand J Urol Nephrol. 1995;29:7-12.
6. Vasan RS, Beiser A, Seshadri S, et al. Residual lifetime risk for developing hypertension in middle-aged women and men: the Framingham Heart Study. JAMA. 2002;287:1003-1010.
7. National Diabetes Information Clearinghouse (NDIC). National Diabetes Statistics. NIH Publication No. 06-3892. November 2005. Available at: http://diabetes.niddk.nih.gov/dm/pubs/statistics. Accessed November 4, 2005.
8. 1A-adrenergic antagonist. Urology. 1998;51:861-872.
9. Foglar R, Shibata K, Horie K, Hirasawa A, Tsujimoto G. Use of recombinant α1-adrenoreceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy. Eur J Pharmacol. 1995;288:201-207.
10. Richardson CD, Donatucci CF, Page SO, Wilson KH, Schwinn DA. Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned alpha 1-adrenergic receptor subtypes. Prostate. 1997;33:55-59.
11. Hatano A, Takahashi H, Tamaki M, Komeyama T, Koizumi T, Takeda M. Pharmacological evidence of distinct alpha 1-adrenoreceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol. 1994;113:723-728.
12. 1d-subtype in filling symptoms and effects of ageing on vascular expression. BJU Int. 2000;85(suppl 2):6-11.
13. Boyle P, Lawrence G, Gould AL, Roehrborn CG. Prostate volume predicts outcome of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology. 1996;48:398-405.
14. Avodart [package insert]. Research Triangle Park, NC. GlaxoSmithKline; 2005.
15. Proscar [package insert]. Whitehouse Station, NJ: Merck & Co, Inc; 2004.
16. Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrinol Metab. 2004;89:2179-2184.
17. Barkin J, Guimaraes M, Jacobi G, Pushkar D, Taylor S, van Vierssen Trip OB. Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual Salpha-reductase inhibitor dutasteride. Eur Urol. 2003;44:461-466.
18. Kirby RS, Roehrborn C, Boule P, et al; Prospective European Doxazosin and Combination Therapy Study Investigators. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology. 2003;61:119-126.
19. McConnell JD, Roehrborn CG, Bautista OM, et al; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349:2387-2398.
20. Milani S, Djavan B. Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists. BJU Int. 2005;95(suppl 4): 29-36.
21. Lepor H, Kaplan SA, Klimberg I, et al. Doxazosin for benign prostatic hyperplasia: long-term efficacy and safety in hypertensive and normotensive patients. The Multicenter Study Group. J Urol. 1997;157:525-530.
22. de Mey C. Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH. Eur Urol. 1998;34(suppl 2):18-28.
23. Kirby RS. Terazosin in benign prostatic hyperplasia: effects on blood pressure in normotensive and hypertensive men. Br J Urol. 1998;82:373-379.
24. 1-blocker. World J Urol. 2002;19:405-412.
25. Lepor H. Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia, Terazosin Research Group. Urology. 1995;45:406-413.
26. Roehrborn CG, Oesterling JE, Auerbach S, et al. The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group. Urology. 1996;47:159-168.
27. Kaplan SA, D'Alisera PM. Tolerability of α-blockade with doxazosin as a therapeutic option for symptomatic benign prostatic hyperplasia in the elderly patient: a pooled analysis of seven double-blind, placebo-controlled studies. J Gerontol A Biol Sci Med Sci. 1998;53: M201-M206.
28. Narayan P, O'Leary MP, Davidai G. Early efficacy of tamsulosin versus terazosin in the treatment of men with benign prostatic hyperplasia: a randomized, open-label trial. J Appl Res. 2005;5:237-245.
29. van Kerrebroec P, Jardin A, van Cangh P, Laval KU; ALFORTI Study Group. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. Eur Urol. 2002;41:54-60.
30. Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int. 2003;92:257-261.
31. Jardin A, Bensadoun H, Delauche-Cavallier MC, Attali P. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group. Br J Urol. 1993;72(5 Pt 1):615-620.
32. Jardin A, Bensadoun H, Delauche-Cavallier MC, Stalla-Bourdillon A, Attali P. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF group. Br J Urol. 1994;74: 579-584.
33. Lukacs B, Grange JC, McCarthy C, Comet D. Clinical uroselectivity: a 3-year follow-up in general practice. BPA Group in General Practice. Eur Urol. 1998;33(suppl 2):28-33.
34. 1-blocker alfuzosin in symptomatic patients with BPH. Italian Alfuzosin Cooperative Group. Eur Urol. 2000;37:680-686.
35. Uroxatral [package insert]. New York, NY: Sanofi-Synthelabo, Inc; 2003.
36. Samli MM, Dincel C. Terazosin and doxazosin in the treatment of BPH: results of a randomized study with crossover in non-responders. Urol Int. 2004;73:125-129.
37. deReijke TM, Klarskov P. Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. BJU Int. 2004;93: 757-762.
38. 1-adrenoceptors in humans. Naunyn-Schmiedeberg's Arch Pharmacol. 1996;354:557-561.
39. Harada K, Ohmori M, Kitoh Y, Sugimoto K, Fujimura A. A comparison of the antagonistic activities of tamsulosin and terazosin against human vascular α1-adrenoceptors. Jpn J Pharmacol. 1999;80: 209-215.
40. Wilt TJ, Mac Donald R, Rutks I. Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev. 2003;(1):CD002081.
41. Narayan P, Bruskewitz R. A comparison of two phase III multicenter, placebo-controlled studies of tamsulosin in BPH. Adv Ther. 2000;17:287-300.
42. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology. 1998;51:901-906.
43. Narayan P, Evans CP, Moon T. Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. J Urol. 2003;170(2 Pt 1):498-502.
44. Debruyne F, Barkin J, van Erps P, Reis M, Tammela TL, Roehrborn C; ARIA3001, ARIA3002 and ARIB3003 Study Investigators. Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol. 2004;46:488-494.
45. Kaplan SA. Salpha-reductase inhibitors: what role should they play? Urology. 2001;58(6 suppl 1):65-70.
46. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med. 1992;327:1185-1191.
47. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group. Prostate. 1993;22:291-299.
48. Roehrborn CG, Boyle P, Nickel JC, Hoefnerk, Andriole G; ARIA3001, ARIA3002 and ARIA3003. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:434-441.
49. Rigatti P, Brausi M, Scarpa RM, Porru D, Schumacher H, Rizzi CA; MICTIS Study Group. A comparison of the efficacy and tolerability of tamsulosin and finasteride in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2003;6:315-323.
50. Lam JS, Romas NA, Lowe FC. Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up. Urology. 2003;61: 354-358.
51. Desgrandchamps F. Who will benefit from combination therapy? The role of 5 alpha reductase inhibitors and alpha blockade: a reflection from MTOPS. Curr Opin Urol. 2004;14:17-20.
52. Campbell AJ. Drug treatment as a cause of falls in old age. A review of the offending agents. Drugs Aging. 1991;1:289-302.
53. Mets TF. Drug-induced orthostatic hypotension in older patients. Drugs Aging. 1995;6:219-228.
54. Man In't Veld AJ, van der Camme TJ, van Loon K. Drug treatment of hypertension in the elderly: the role of α-adrenoceptor blockade. Br J Urol. 1998;81(suppl 1):21-25.
55. Lowe FC. Coadministration of tamsulosin and three antihypertensive agents in patients with benign prostatic hyperplasia: pharmacodynamic effect. Clin Ther. 1997; 19:730-742.
56. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology. 1998;51:892-900.
57. Schulman C. Impact of treatment of BPH on sexuality. Prostate Cancer Prostatic Dis. 2001;4(suppl 1):S12-S16.
58. Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. Eur Urol. 1997;31:272-280.
59. Nicolosi A, Glasser DB, Moreira ED, Villa M; Erectile Dysfunction Epidemiology Cross National Study Group. Prevalence of erectile dysfunction and associated factors among men without concomitant diseases: a population study. Int J Impot Res. 2003;15:253-257.
60. Höfner K, Claes H, De Reijke TM, Folkestad B, Speakman MJ; the European Tamsulosin Study Group. Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol. 1999;36:335-341.
61. Djavan B. Is transurethral microwave thermotherapy an alternative to medical therapy for patients with benign prostatic hyperplasia? Tech Urol. 2000;6:300-306.
62. Jepsen JV, Bruskewitz RC. Surgical and nonsurgical invasive treatment of benign prostatic hyperplasia. Drugs Today (Barc). 1998;34:353-360.
63. Hill B, Belville W, Bruskewitz R, et al. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. J Urol. 2004;171(6 Pt 1): 2336-2340.
64. Cimentepe E, Unsal A, Saglam R. Randomized clinical trial comparing transurethral needle ablation with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: results at 18 months. J Endourol. 2003;17:103-107.
65. Hammadeh MY, Madaan S, Singh M, Philp T. A 3-year follow-up of a prospective randomized trial comparing transurethral electrovaporization of the prostate with standard transurethral prostatectomy. BJU Int. 2000;86:648-651.
66. Gravas S, Laguna MP, de la Rosette JJ. Efficacy and safety of intraprostatic temperature-controlled microwave thermotherapy in patients with benign prostatic hyperplasia: results of a prospective, open-label, single-center study with 1-year follow-up. J Endourol. 2003;17: 425-430.